The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Research analysts at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” ...

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

We review the six best THCp gummies with potent effects and learn about their potent effects, which alleviate pain and ...

In chronic migraine, headaches occur more than 15 days per month. Treatment of chronic migraine is problematic because when used more than a few days a week, acute therapies worsen the headaches in ...

Market OverviewThe Global Generic Drugs Market was valued at $411.99 Billion in 2022 and is projected to reach $613.34 ...